Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
- Status
- UNKNOWN
- Phase
- PHASE2
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Renal Adjuvant MultiPle Arm Randomised Trial
- Status
- RECRUITING
- Phase
- PHASE3
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
- Status
- UNKNOWN
- Phase
- PHASE1
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
- Status
- TERMINATED
- Phase
- PHASE1
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
- Status
- COMPLETED
- Phase
- PHASE1